{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:17:15Z","timestamp":1774595835569,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004748","type":"journal-article","created":{"date-parts":[[2004,4,23]],"date-time":"2004-04-23T15:14:09Z","timestamp":1082733249000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Velnacrine for Alzheimer's disease"],"prefix":"10.1002","author":[{"given":"Jacqueline","family":"Birks","sequence":"first","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine; Wolfson College Linton Road Oxford UK OX2 6UD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon K","family":"Wilcock","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Medicine; John Radcliffe Hospital, Headington 4th Floor Oxford UK OX3 9DU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,4,19]]},"reference":[{"issue":"16","key":"10.1002\/14651858.CD004748-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/archinte.1995.00430160102010","article-title":"Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease A double-blind, placebo-controlled study Mentane Study Group","volume":"155","author":"Antuono","year":"1995","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004748-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0009-9236(95)90201-5","article-title":"Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease","volume":"58","author":"Clipp","year":"1995","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004748-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(94)91027-8","article-title":"Alzheimer's disease and caregiver time [letter]","volume":"343","author":"Moore","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004748-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/j.1552-4604.1990.tb03620.x","article-title":"Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings","volume":"30","author":"Cutler","year":"1990","journal-title":"Journal of Clinical Pharmacology"},{"issue":"8-9","key":"10.1002\/14651858.CD004748-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/BF01291795","article-title":"Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial","volume":"103","author":"Zemlan","year":"1996","journal-title":"Journal of Neural Transmission"},{"issue":"21","key":"10.1002\/14651858.CD004748-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/0024-3205(96)00166-X","article-title":"Double-blind placebo-controlled study of velnacrine in Alzheimer's disease","volume":"58","author":"Zemlan","year":"1996","journal-title":"Life Sciences"},{"issue":"1-2","key":"10.1002\/14651858.CD004748-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02245293","article-title":"Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease","volume":"108","author":"Ebmeier","year":"1992","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD004748-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1749-6632.1991.tb00230.x","article-title":"Potential clinical use of an adrenergic\/cholinergic agent (HP 128) in the treatment of Alzheimer's disease","volume":"640","author":"Huff","year":"1991","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD004748-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1749-6632.1991.tb00229.x","article-title":"Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease","volume":"640","author":"Murphy","year":"1991","journal-title":"New York Academy of Sciences"},{"issue":"3","key":"10.1002\/14651858.CD004748-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-4580(90)90924-O","article-title":"Postural blood pressure drop as a possible predictor of response to cholinergic therapy in Alzheimer's disease","volume":"11","author":"Pomara","year":"1990","journal-title":"Neurobiology of Aging"},{"issue":"10","key":"10.1002\/14651858.CD004748-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/j.1552-4604.1989.tb03261.x","article-title":"The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent","volume":"29","author":"Puri","year":"1989","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004748-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0197-4580(90)90954-X","article-title":"Clinical experience with a cholinesterase inhibitor (HP 029) in the treatment of Alzheimer's disease: can it make a difference?","volume":"11","author":"Richter","year":"1990","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD004748-BIB0013|cit13","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD004748-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.114.512.797","article-title":"The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects","volume":"114","author":"Blessed","year":"1968","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004748-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in treatment assignment in controlled clinical trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004748-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD004748-BIB0017|cit17","first-page":"218","article-title":"Clinical Global Assessment Scale (CGI)","volume-title":"Guy W, editor(s). ECDEU Assessment Manual for Psychopharmacology","author":"Guy W. Clinical Global Assessment Scale (CGI)","year":"1976"},{"key":"10.1002\/14651858.CD004748-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"10.1002\/14651858.CD004748-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004748-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(94)91027-8","article-title":"Alzheimer's disease and caregiver time","volume":"343","author":"Moore","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004748-BIB0021|cit21","first-page":"766","article-title":"Single dose safety, tolerance, and pharmacokinetics of HO 029 in elderly men: a potential Alzheimer's agent","volume":"44","author":"Puri","year":"1988","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD004748-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/j.1552-4604.1989.tb03328.x","article-title":"Single dose safety, tolerance, and pharmacokinetics of HO 029 in young men: a potential Alzheimer's agent","volume":"29","author":"Puri","year":"1989","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004748-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"The global deterioration scale for assessment of primary degenerative dementia","volume":"139","author":"Reisberg","year":"1982","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD004748-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ana.410070516","article-title":"Pathological verification of ischemic score in differentiation of dementias","volume":"7","author":"Rosen","year":"1980","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004748-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD004748-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004748","article-title":"Velnacrine for Alzheimer's Disease","author":"Birks","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004748\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:39:24Z","timestamp":1628545164000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004748"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2004,4,19]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004748","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,19]]}}}